181 related articles for article (PubMed ID: 28991893)
21. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
22. Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States.
Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
Clin Ther; 2017 Feb; 39(2):303-310. PubMed ID: 28065438
[TBL] [Abstract][Full Text] [Related]
23. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
24. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
[TBL] [Abstract][Full Text] [Related]
25. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Marouf A; Molinari N; Sibon D; Cottereau AS; Kanoun S; Antoine C; Debureaux PE; Cavalieri D; Fornecker LM; Casasnovas RO; Herbaux C; Amorim S; Rossi C; Bouscary D; Brice P; Ghesquieres H; Tamburini J; Deau B
Br J Haematol; 2023 Jul; 202(2):379-383. PubMed ID: 37192755
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Vinti L; Pagliara D; Buffardi S; Di Ruscio V; Stocchi F; Mariggiò E; Parasole R; Di Matteo A; Petruzziello F; Paganelli V; De Vito R; Del Bufalo F; Strocchio L; Locatelli F
Pediatr Blood Cancer; 2022 Apr; 69(4):e29557. PubMed ID: 35107876
[TBL] [Abstract][Full Text] [Related]
27. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
[TBL] [Abstract][Full Text] [Related]
28. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient].
Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T
Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873
[TBL] [Abstract][Full Text] [Related]
29. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.
Wagner CB; Boucher K; Nedved A; Micallef IN; Desai S; Hatic H; Goyal G; Zacholski E; Fegley A; Sigmund AM; Bond DA; Samuels C; Kamdar MK; Ba Aqeel S; Torka P; MacDougall K; Borogovac A; Rajeeve S; Sundaram S; Fedak K; Modi D; Travers E; Ayyappan S; Chilakamarri N; Brem EA; Ermann DA; Fitzgerald LA; Hu B; Stephens DM; Shah H
Haematologica; 2023 Nov; 108(11):3025-3032. PubMed ID: 37102592
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
31. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
32. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
Picardi M; Della Pepa R; Giordano C; Pugliese N; Mortaruolo C; Trastulli F; Rascato MG; Cappuccio I; Raimondo M; Memoli M; Monteverde M; Mascolo M; Pane F
Blood Adv; 2019 May; 3(9):1546-1552. PubMed ID: 31088808
[TBL] [Abstract][Full Text] [Related]
34. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R; Zinzani PL; Fanale MA; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Zhang Y; Ricart AD; Balakumaran A; Moskowitz CH;
J Clin Oncol; 2017 Jul; 35(19):2125-2132. PubMed ID: 28441111
[TBL] [Abstract][Full Text] [Related]
36. Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
Shah H; Jang H; Singh P; Kosti J; Kin A; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Ramchandren R; Kim S; Deol A
Leuk Lymphoma; 2022 Apr; 63(4):813-820. PubMed ID: 34781825
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Onishi M; Graf SA; Holmberg L; Behnia S; Shustov AR; Schiavo K; Philip M; Libby EN; Cassaday RD; Pagel JM; Roden JE; Maloney DG; Green DJ; Till BG; Press OW; Smith SD; Gopal AK
Hematol Oncol; 2015 Dec; 33(4):187-91. PubMed ID: 25236531
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R; Zekri J; Al Saadi R
Expert Opin Biol Ther; 2016 Jun; 16(6):739-45. PubMed ID: 27096887
[TBL] [Abstract][Full Text] [Related]
39. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Nieto Y; Gruschkus S; Valdez BC; Jones RB; Anderlini P; Hosing C; Popat U; Qazilbash M; Kebriaei P; Alousi A; Saini N; Srour S; Rezvani K; Ramdial J; Barnett M; Gulbis A; Shigle TL; Ahmed S; Iyer S; Lee H; Nair R; Parmar S; Steiner R; Dabaja B; Pinnix C; Gunther J; Cuglievan B; Mahadeo K; Khazal S; Chuang H; Champlin R; Shpall EJ; Andersson BS
Haematologica; 2022 Apr; 107(4):899-908. PubMed ID: 33951890
[TBL] [Abstract][Full Text] [Related]
40. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]